Dominari Holdings Inc. (NASDAQ:DOMH) Short Interest Down 33.7% in May

Dominari Holdings Inc. (NASDAQ:DOMH) was the recipient of a significant decrease in short interest in May. As of May 29th, there was short interest totaling 349,871 shares, a decrease of 33.7% from the May 14th total of 527,421 shares. Approximately 3.5% of the company’s stock are sold short. Based on an average daily volume of 141,717 shares, the short-interest ratio is currently 2.5 days.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Renaissance Technologies LLC raised its position in shares of Dominari by 59.1% during the first quarter. Renaissance Technologies LLC now owns 132,362 shares of the company’s stock valued at $430,000 after buying an additional 49,162 shares during the last quarter. PFG Investments LLC raised its position in shares of Dominari by 36.3% during the first quarter. PFG Investments LLC now owns 14,475 shares of the company’s stock valued at $47,000 after buying an additional 3,855 shares during the last quarter. Creek Drive Management Group LLC acquired a new position in shares of Dominari during the fourth quarter valued at about $1,861,000. NewEdge Advisors LLC acquired a new position in shares of Dominari during the fourth quarter valued at about $50,000. Finally, Oxford Asset Management LLP acquired a new position in shares of Dominari during the fourth quarter valued at about $120,000. Institutional investors and hedge funds own 42.48% of the company’s stock.

Dominari Price Performance

Dominari stock opened at $3.20 on Wednesday. The firm has a market cap of $72.35 million, a price-to-earnings ratio of -0.79 and a beta of 0.80. Dominari has a fifty-two week low of $2.68 and a fifty-two week high of $8.40. The firm has a fifty day moving average price of $3.17 and a two-hundred day moving average price of $3.59.

Dominari (NASDAQ:DOMH) last released its earnings results on Wednesday, May 13th. The company reported ($2.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($1.94). The firm had revenue of $35.81 million for the quarter, compared to analyst estimates of $35.81 million. Dominari had a negative return on equity of 206.20% and a negative net margin of 31.37%.

Dominari Announces Dividend

The business also recently disclosed a special dividend, which was paid on Friday, May 29th. Stockholders of record on Friday, May 15th were given a dividend of $0.31 per share. The ex-dividend date of this dividend was Friday, May 15th.

Wall Street Analyst Weigh In

Separately, Wall Street Zen raised shares of Dominari from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has an average rating of “Sell”.

Dominari Company Profile

Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2.